Business
Alnylam Appoints Tolga Tanguler Chief Commercial Officer and Also Announces New CEMEA, Medical Affairs, and Compliance Leaders
- Strong Commercial and Medical Team in Place to Execute on Three Ongoing Global Launches and Advancement of Innovative Pipeline of RNAi Therapeutics –
About this update from Alnylam Pharmaceuticals, Inc.
[{"type":"text","content":"\n- Strong Commercial and Medical Team in Place to Execute on Three Ongoing Global Launches and Advancement of Innovative Pipeline of RNAi Therapeutics –\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the appointment of Tolga Tanguler to the role of Chief Commercial Officer where he will lead global marketing, sales, market access, commercial operations, training, new product commercialization and commercial strategy for the Company. Tolga will also join the Company’s Management Board. In addition, Alnylam has recruited an experienced team of leaders across key functions, including: Kasha Witkos, Senior Vice President and Head of Canada, Europe, Middle East and Africa (CEMEA); Salil Patel, Senior Vice President and Head of Medical Affairs; and Agnieszka Gallagher, Chief Ethics and Compliance Officer.\n\n“After an in-depth and comprehensive search, we have selected Tolga Tanguler, a dynamic and highly skilled commercial leader to join Alnylam. With over 20 years of global pharmaceutical and biotech experience, most recently at Pfizer and Alexion, Tolga's considerable success commercializing multiple rare, specialty and common disease products positions him as an excellent choice for this key role,” said John Maraganore, Ph.D., Chief Executive Officer at Alnylam. “With Tolga, Kasha, Salil and Aggie joining Alnylam, we have now rounded out our world-class leadership team across our commercial, medical and compliance expertise areas. Together, these outstanding leaders stand poised to support the ongoing global launches of our three marketed products and promising pipeline of innovative medicines addressing a range of patient needs, while we continue on our path towards profitability.”\n\nTolga Tanguler, Chief Commercial Officer\nTolga Tanguler has a strong track record of success in the global pharmaceutical and biotech industries, building out commercial capabilities, leading highly functioning teams, and cultivating robust thought leader relationships across multiple specialties. He joins Alnylam from Alexion where he was Senior Vice President, Head of U.S. and launched three new products while building key functions and capabilities and driving over $3 billion in revenue with double digit growth in eight consecutive quarters. Prior to ...